Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Set Targets Not Price Limits, German Industry Pleads

Plans for reference-price group for four anti-TNFs, including adalimumab and etanercept

Executive Summary

Grouping together biosimilar adalimumabs and etanercepts with patented biologics in the same reference-price group in Germany threatens to remove biosimilars’ market advantage and weaken competition, local industry fears.

You may also be interested in...



German Doctors Fear ‘Nocebo’ Impact From Substitution

Switching German patients from one biologic to another without involving their doctor could cause patients to perceive biosimilars as having inferior safety and efficacy, a local physicians’ body is warning. 

Bio Substitution Plan Would Put Germany On ‘Wrong Track’

Plans for substituting biological drugs at pharmacy level that have been passed by Germany’s lower house of parliament threaten to undo the good work done to date in winning trust in biosimilars, local industry association Pro Biosimilars fears.

Pressure Mounts For German Tender Reforms

Germany’s off-patent industry association, Pro Generika, is finding ample support for its position that by awarding tender contracts to exclusive suppliers, health insurance funds are contributing to drug shortages in the country.

Topics

Latest News
UsernamePublicRestriction

Register

GB149226

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel